ND

Nilam Devi

Active Director Director DIN 10746809
DIN 10746809 First appointment Sep 2024 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2024
Shareholding value •••• Premium profile

About Nilam Devi

Data last updated:

Nilam Devi is a Director at Autocrat Pharmaceuticals Private Limited (since 2024). The company operates in Trading. Autocrat Pharmaceuticals Private Limited reported revenue of ₹9.1 Lakh (FY 2023).

DIN 10746809
Primary Designation Director
Industry Trading
First Appointment 10 Sep 2024
Oldest Company Age 10 yrs
Largest company Autocrat Pharmaceuticals Private Limited · ₹9.1 Lakh (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director10 Sep 20242016₹9.1 Lakh (FY 2023)Active

Board colleagues of Nilam Devi

Directorship timeline

Open interactive timeline →
Autocrat Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Nilam Devi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nilam Devi

Nilam Devi currently holds 1 directorship: Autocrat Pharmaceuticals Private Limited (Director, since 10 Sep 2024, revenue ₹9.1 Lakh (FY 2023)).

Nilam Devi was first appointed on 10 Sep 2024 as Director at Autocrat Pharmaceuticals Private Limited.

The current boards of Nilam Devi's companies include Chandan Kumar Kaushik (Autocrat Pharmaceuticals Private Limited), Niraj Lal Yadav (Autocrat Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available